Abbott Laboratories
ABT | NYSE
$102.88
+$0.27 (+0.26%)
Sep 21, 2026, 12:40 PM ET · Market open
Company Profile
Abbott Laboratories, along with its affiliated entities, is a global healthcare enterprise dedicated to the research, development, manufacturing, and worldwide distribution of a diverse portfolio of health solutions. The company operates through four primary divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. In the Established Pharmaceutical Products segment, Abbott provides generic medications designed to treat a wide array of conditions, including pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorders, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine. This segment also supplies the anti-infective clarithromycin, influenza vaccines, and products aimed at regulating colon physiology. The Diagnostic Products division offers a comprehensive suite of diagnostic tools. These include laboratory systems for immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and quantify infectious agents. Additionally, this segment provides point-of-care systems, blood testing cartridges, rapid lateral flow testing products, and specialized molecular point-of-care tests for pathogens such as HIV, SARS-CoV-2, influenza A and B, RSV, and strep A. Its offerings also extend to cardiometabolic test systems, drug and alcohol screening solutions, remote patient monitoring, consumer self-test systems, and sophisticated informatics and automation solutions for laboratory use. The Nutritional Products segment is responsible for delivering nutritional formulations tailored for both pediatric and adult populations. Finally, the Medical Devices segment develops and commercializes rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular ailments. It also supplies diabetes care products and neuromodulation devices designed for the management of chronic pain and movement disorders. Founded in 1888, Abbott Laboratories maintains its corporate headquarters in North Chicago, Illinois.
Key Executives
| Name | Position |
|---|---|
| Robert Ford | Executive Chairman & CEO |
| Philip Boudreau | Chief Financial Officer & Executive Vice President of Finance |
| Sabina Ewing | Senior Vice President of Business & Technology Services and Chief Information Officer |
| Christopher J. Scoggins | Executive Vice President of Diabetes Care |
| Daniel Gesua Sive Salvadori | Executive Vice President and Group President of Established Pharmaceuticals & Nutritional Products |
| Elizabeth Cushman | Executive Vice President, General Counsel & Secretary |
| Erica L. Battaglia | Vice President and Chief Ethics & Compliance Officer |
| Lisa D. Earnhardt | Executive Vice President & Group President of Medical Devices |
| Mary K. Moreland | Executive Vice President of Human Resources |
| Melissa Brotz | Senior Vice President of Global Marketing & External Affairs |
| Michael Comilla | Vice President of Investor Relations. |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 03, 2026 | 4 | Filing |
| Sep 03, 2026 | 4 | Filing |
| Aug 27, 2026 | 4 | Filing |
| Aug 20, 2026 | 8-K | Current Report |
| Aug 13, 2026 | 4 | Filing |
| Jul 28, 2026 | 10-Q | Quarterly Report |
| Jul 16, 2026 | 8-K | Current Report |
| Jul 01, 2026 | 4 | Filing |
| Jul 01, 2026 | 4 | Filing |
| Jul 01, 2026 | 4 | Filing |
Abbott Laboratories
| Country | United States |
| IPO Date | Mar 16, 1980 |
| Industry | Medical - Devices |
| Sector | Healthcare |
| Employees | 115,000 |
| CEO | Robert Ford |
Contact Details
100 Abbott Park Road Abbott Park,
Illinois 60064-6400 United States
Stock Details
| Ticker Symbol | ABT |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000001800 |
| CUSIP Number | 002824100 |
| ISIN Number | US0028241000 |
| SIC Code | 2834 |
Recent News
- 6 hours ago / zacks.comWhy Investors Need to Take Advantage of These 2 Medical Stocks Now
- 3 days ago / fool.comWhy Wall Street Is Becoming Even More Bullish About This Dividend King
- 4 days ago / prnewswire.comAbbott declares 411th consecutive quarterly dividend
- 5 days ago / zacks.comIs Abbott (ABT) a Buy as Wall Street Analysts Look Optimistic?
- 6 days ago / zacks.comAbbott (ABT) Rises As Market Takes a Dip: Key Facts
- 7 days ago / reuters.comAbbott to pay $384 mln over contaminated infant formula allegations, US Justice Dept says
- 7 days ago / prnewswire.comAbbott reaches agreement with Department of Justice to resolve claims relating to 2022 infant formula recall
- 10 days ago / zacks.comInvestors Heavily Search Abbott Laboratories (ABT): Here is What You Need to Know
- 12 days ago / zacks.comAbbott Receives FDA Nod for TactiFlex Duo: Stock to Gain?
- 13 days ago / zacks.comHere's Why Abbott (ABT) Fell More Than Broader Market
Add to Watchlist
Select watchlists to add or remove ABT